Safety, Tolerability, and Efficacy of Tocilizumab in Rheumatoid Arthritis: An Open-Label Phase 4 Study in Patients from the Middle East

Table 3

Laboratory parameters.

Hematology parameter	Mean (SD) changes from baseline to week 24
Hemoglobin, g/dL	0.77 (1.16)	0.001
Lymphocytes, %	9.72 (16.44)	0.001
Neutrophil count, ×10^3/L	−1.60 (2.48)	0.0001
Platelet count, ×10^3/L	−99.7 (73.0)	<0.0001
White blood cell count, ×10^3/L	−1.58 (2.46)	0.0001
Albumin, g/L	−1.56 (6.91)	0.005
Alkaline phosphatase, IU/L	−20.7 (28.8)	0.009
Indirect bilirubin, mol/L	2.43 (3.88)	<0.0001
Total bilirubin, mol/L	3.42 (5.6)	<0.0001
Total protein, g/L	−3.04 (5.51)	0.0001

SD, standard deviation.
was considered statistically significant based on the Friedman test (analysis of variance).